liu.seSearch for publications in DiVA
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial
Klinikum Carl Gustav Carus, Germany.
Carol Davila University of Medical and Pharm, Romania.
Hospital Britanico Buenos Aires, Argentina.
Virga Jessaziekenhuis, Belgium.
Vise andre og tillknytning
2014 (engelsk)Inngår i: Journal of Neurology, ISSN 0340-5354, E-ISSN 1432-1459, Vol. 261, nr 11, s. 2101-2111Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Studies suggest that patients with relapsing-remitting multiple sclerosis (RRMS) who do not benefit from other disease-modifying treatments (DMTs) may benefit from converting to glatiramer acetate (GA). COPTIMIZE was a 24-month observational study designed to assess the disease course of patients converting to GA 20 mg daily from another DMT. Eligible patients had converted to GA and had received prior DMT for 3-6 months, depending on the reasons for conversion. Patients were assessed at baseline and at 6, 12, 18, and 24 months. In total, 672 patients from 148 centers worldwide were included in the analysis. Change of therapy to GA was prompted primarily by lack of efficacy (53.6 %) or intolerable adverse events (AEs; 44.8 %). Over a 24-month period, 72.7 % of patients were relapse free. Mean annual relapse rate decreased from 0.86 [95 % confidence interval (CI) 0.81-0.91] before the change to 0.32 (95 % CI 0.26-0.40; p less than 0.0001) at last observation, while the progression of disability was halted, as the Kurtzke Expanded Disability Status Scale (EDSS) scores remained stable. Patients improved significantly (p less than 0.05) on measures of fatigue, quality of life, depression, and cognition; mobility scores remained stable. The results indicate that changing RRMS patients to GA is associated with positive treatment outcomes.

sted, utgiver, år, opplag, sider
Springer Verlag (Germany) , 2014. Vol. 261, nr 11, s. 2101-2111
Emneord [en]
Disease-modifying therapy; Glatiramer acetate; Multiple sclerosis; RRMS
HSV kategori
Identifikatorer
URN: urn:nbn:se:liu:diva-112822DOI: 10.1007/s00415-014-7446-0ISI: 000344808400006PubMedID: 25119836OAI: oai:DiVA.org:liu-112822DiVA, id: diva2:777005
Merknad

Funding Agencies|Teva Pharmaceuticals Industries Ltd., Petach Tikva, Israel

Tilgjengelig fra: 2015-01-08 Laget: 2014-12-17 Sist oppdatert: 2017-12-05

Open Access i DiVA

fulltext(410 kB)395 nedlastinger
Filinformasjon
Fil FULLTEXT01.pdfFilstørrelse 410 kBChecksum SHA-512
7faf561aead5478b5eba79720e915b04a0a3cffdb68fab7bf714a0945a8883107a2947675a8ba055ccb5ca7021300affcd211256f875cc28bd0107970378dca9
Type fulltextMimetype application/pdf

Andre lenker

Forlagets fulltekstPubMed

Personposter BETA

Landtblom, Anne-Marie

Søk i DiVA

Av forfatter/redaktør
Landtblom, Anne-Marie
Av organisasjonen
I samme tidsskrift
Journal of Neurology

Søk utenfor DiVA

GoogleGoogle Scholar
Totalt: 395 nedlastinger
Antall nedlastinger er summen av alle nedlastinger av alle fulltekster. Det kan for eksempel være tidligere versjoner som er ikke lenger tilgjengelige

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 258 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf